Safety and immunogenicity of rSh28GST antigen in humans: Phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis

PLoS Neglected Tropical Diseases

Volumn 6, Issue 7, 2012, Pages

  Riveau, Gilles ^a   Deplanque, Dominique ^a,b   Remoué, Franck ^a   Schacht, Anne Marie ^a   Vodougnon, Hubert ^b   Capron, Monique ^a   Thiry, Michel ^c   Martial, Joseph ^c   Libersa, Christian ^a,b   Capron, André ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c EUROGENTEC S A   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBIOTIC AGENT; GAMMA INTERFERON; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PLACEBO; SCHISTOSOMA VACCINE; TRANSFORMING GROWTH FACTOR BETA1; 28 KDA GLUTHATHIONE S TRANSFERASE ANTIGEN, SCHISTOSOMA HAEMATOBIUM; 28 KDA GLUTHATHIONE S-TRANSFERASE ANTIGEN, SCHISTOSOMA HAEMATOBIUM; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; CYTOKINE; HELMINTH ANTIBODY; HELMINTH PROTEIN; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; HYPERTHERMIA; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE INDURATION; MALE; NORMAL HUMAN; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS; SIDE EFFECT; SWELLING; TH2 CELL; ADOLESCENT; ANIMAL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG TOXICITY; GENETICS; HUMAN EXPERIMENT; IMMUNOLOGY; METHODOLOGY; SCHISTOSOMIASIS HAEMATOBIA; SECRETION (PROCESS); SERODIAGNOSIS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; CYTOKINES; DRUG TOXICITY; GLUTATHIONE TRANSFERASE; HELMINTH PROTEINS; HUMAN EXPERIMENTATION; HUMANS; MALE; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMIASIS HAEMATOBIA; VACCINATION; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84864578533     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001704     Document Type: Article

References (28)

1. Redman CA, Robertson A, Fallon PG, Modha J, Kusel JR, et al. (1996) Praziquantel: An urgent and exciting challenge. Parasitology Today 12: 14-20.
2. Stelma FF, Talla I, Sow S, Kongs A, Niang M, et al. (1995) Efficacy and Side Effects of Praziquantel in an Epidemic Focus of Schistosoma mansoni. The American Journal of Tropical Medicine and Hygiene 53: 167-170.
3. Bergquist NR, Colley DG, (1998) Schistosomiasis Vaccine:Research to Development. Parasitology Today 14: 99-104.
4. Fallon PG, Sturrock RF, Capron A, Niang M, Doenhoff MJ, (1995) Short Report: Diminished Susceptibility to Praziquantel in a Senegal Isolate of Schistosoma mansoni. The American Journal of Tropical Medicine and Hygiene 53: 61-62.
5. Sabra AN, Botros SS, (2008) Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure. Journal of Parasitology 94: 537-541.
6. Capron A, Riveau GJ, Bartley PB, McManus DP, (2002) Prospects for a schistosome vaccine. Current Drug Targets Immune, Endocrine and Metabolic Disorders 2: 281-290.
7. Balloul JM, Sondermeyer P, Dreyer D, Capron M, Grzych JM, et al. (1987) Molecular cloning of a protective antigen of schistosomes. Nature 326: 149-153.
8. Trottein F, Vaney M-C, Bachet B, Pierce R-J, Colloc'h N, et al. (1992) Crystallization and preliminary X-ray diffraction studies of a protective cloned 28 kDa glutathione S-transferase from Schistosoma mansoni. Journal of Molecular Biology 224: 515-518.
9. Xu CB, Verwaerde C, Gras-Masse H, Fontaine J, Bossus M, et al. (1993) Schistosoma mansoni 28-kDa glutathione S-transferase and immunity against parasite fecundity and egg viability. Role of the amino- and carboxyl-terminal domains. Journal of Immunology (Baltimore, Md: 1950) 150: 940-949.
10. Dupré L, Herv M, Schacht AM, Capron A, Riveau G, (1999) Control of schistosomiasis pathology by combination of Sm28GST DNA immunization and praziquantel treatment. The Journal of Infectious Diseases 180: 454-463.
11. Boulanger D, Reid GD, Sturrock RF, Wolowczuk I, Balloul JM, et al. (1991) Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni. Parasite Immunology 13: 473-490.
12. Boulanger D, Warter A, Trottein F, Mauny F, Brémond P, et al. (1995) Vaccination of patas monkeys experimentally infected with Schistosoma haematobium using a recombinant glutathione S-transferase cloned from S. mansoni. Parasite Immunology 17: 361-369.
13. De Bont J, Vercruysse J, Grzych JM, Meeus PF, Capron A, (1997) Potential of a recombinant Schistosoma bovis-derived glutathione S-transferase to protect cattle against experimental and natural S. mattheei infection. Parasitology 115 (Pt 3): 249-255.
14. Grzych JM, De Bont J, Liu J, Neyrinck JL, Fontaine J, et al. (1998) Relationship of impairment of schistosome 28-kilodalton glutathione S-transferase (GST) activity to expression of immunity to Schistosoma mattheei in calves vaccinated with recombinant Schistosoma bovis 28-kilodalton GST. Infection and Immunity 66: 1142-1148.
15. Riveau G, Capron A, (1996) Vaccination against schistosomiasis: concepts and strategies. Concepts in Vaccine Design Berlin, New York S.H.E. Kaufmann %7 Walter de Gruyter and co.
16. Capron A, Riveau G, Capron M, Trottein F, (2005) Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends in Parasitology 21: 143-149.
17. Grzych JM, Grezel D, Xu CB, Neyrinck JL, Capron M, et al. (1993) IgA antibodies to a protective antigen in human Schistosomiasis mansoni. Journal of Immunology (Baltimore, Md: 1950) 150: 527-535.
18. Remoué F, Rogerie F, Gallissot MC, Guyatt HL, Neyrinck JL, et al. (2000) Sex-dependent neutralizing humoral response to Schistosoma mansoni 28GST antigen in infected human populations. The Journal of Infectious Diseases 181: 1855-1859.
19. Dunne DW, Hagan P, Abath FG, (1995) Prospects for immunological control of schistosomiasis. Lancet 345: 1488-1491.
20. WHO (1995) Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products- Sixth Report. pp. 97-137 WHO Technical Report Series, No. 850, Annex 3.
21. WHO (1996) Guidelines for Good Clinical Practice (3 errata post step 4 included). ICH Harmonised Tripartite Guideline. In: Committee ICHS, editor.
22. FDA (2007) Guidance for Industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials.
23. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB, (2004) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. The New England Journal of Medicine 351: 1548-1563.
24. Fiejka M, Fiejka E, Dougaszek M, (1996) Effect of aluminium hydroxide administration on normal mice: tissue distribution and ultrastructural localization of aluminium in liver. Pharmacology & Toxicology 78: 123-128.
25. Romagnani S, (1996) Development of Th 1- or Th 2-dominated immune responses: what about the polarizing signals? International Journal of Clinical & Laboratory Research 26: 83-98.
26. Gupta RK, Rost BE, Relyveld E, Siber GR, (1995) Adjuvant properties of aluminum and calcium compounds. Pharmaceutical Biotechnology 6: 229-248.
27. Romagnani S, Parronchi P, D'Elios MM, Romagnani P, Annunziato F, et al. (1997) An update on human Th1 and Th2 cells. International Archives of Allergy and Immunology 113: 153-156.
28. Capron A, (1998) Schistosomiasis: forty years' war on the worm. Parasitology Today (Personal Ed) 14: 379-384.